ChanBio

Company Overview

Snapshot

Founded in January 2012 by Oren Bogin, ChanBio operates with 1–10 employees. The company has secured funding across two rounds from two investors. In November 2013, ChanBio joined the Merck Serono Israel Bioincubator, a significant milestone for its early development.

Business overview

ChanBio is a biopharmaceutical company focused on developing functional antibody-based modulators for ion channels and G-protein-coupled receptors (GPCRs). The company's core technology aims to create treatments for multiple sclerosis, as well as other autoimmune, cardiovascular, cancer-related, and pain disorders. Operating within the biopharmaceutical sector, ChanBio serves the health tech and life sciences markets, with a particular focus on pharmaceuticals.

Strategic signal

In November 2013, ChanBio joined the Merck Serono Israel Bioincubator. This move signals strategic validation and access to critical resources and expertise, indicating a strong foundation for the company's research and development efforts in biopharmaceuticals.

Company Intelligence Q&A

Who founded ChanBio?

ChanBio was founded by Oren Bogin, who serves as its CEO.

When was ChanBio founded?

ChanBio was founded in January 2012.

What is ChanBio's primary focus in biopharmaceuticals?

ChanBio is dedicated to developing functional antibody-based modulators active on ion channels and G-protein-coupled receptors (GPCRs), with a focus on treatments for multiple sclerosis and other autoimmune, cardiovascular, cancer-related, and pain disorders.

What significant corporate development occurred in November 2013?

In November 2013, ChanBio joined the Merck Serono Israel Bioincubator, as reported by Globes.co.il.